Cash, Cash Equivalents, and Short-term Investments: Ended 2024 with $47.2 million. Post-Transaction Cash Range: Expected to be $170 million to $180 million. FYARRO Net Product Sales (Q4): $7.2 million ...
MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to ...
Aadi will now focus on preserving cash while maximizing its commercial business. Aligned with these pipeline adjustments, the company is reducing its R&D workforce by 80%. Feel unsure about the market ...
Fintel reports that on May 17, 2023, HC Wainwright & Co. reiterated coverage of Aadi Bioscience (NASDAQ:AADI) with a Buy recommendation. As of May 11, 2023, the average one-year price target for Aadi ...
Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot. The company will henceforth be known as Whitehawk ...
Aadi Bioscience (AADI) announced that Kaken Pharmaceutical, an R&D driven pharmaceutical company in Japan, has entered into a stock purchase agreement under which Kaken will acquire Aadi Subsidiary ...
Aadi Bioscience’s Fyarro is on track to fail a phase 2 solid tumor trial, leading the biotech to halt the study and lay off 80% of its R&D workforce. The company had been investigating the approved ...
Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback